1. Market Research
  2. > Biotechnology Market Trends
  3. > Global Pharma and Biotech M&A Trends 2010-2015

Global Pharma and Biotech M&A Trends 2010-2015

  • August 2015
  • -
  • Currentpartnering
  • -
  • 1677 pages

The Global Pharma and Biotech M&A Trends 2010-2015 report provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies.

The Global Pharma and Biotech M&A Trends 2010-2015 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all merger and acquisition deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of M&A dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in M&A as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of M&A deals. The chapter includes numerous case studies to enable understanding of M&A deals.

Chapter 4 provides a review of the leading M&A deals since 2010. Deals are listed by headline value, signed by bigpharma and and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 big pharma companies (with M&A announements) with a brief summary followed by a comprehensive listing of M&A deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive listing of the top 50 big biotech companies (with M&A announements) with a brief summary followed by a comprehensive listing of M&A deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of M&A deals signed and announced since 2010 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the M&A deal.

In addition the report includes a comprehensive listing of all M&A deals announced since 2010. Each listing is organized as an appendix by company A-Z, and industry sector. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in M&A dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about M&A alliances.

Global Pharma and Biotech M&A Trends 2010-2015 report provides the reader with the following key benefits:

In-depth understanding of M&A deal trends since 2010
Analysis of the structure of M&A agreements with numerous real life case studies
Comprehensive access to over 2,500 actual M&A deals entered into by the world’s biopharma companies, together with contract documents if available
Detailed access to actual M&A deals entered into by the leading fifty big pharma and big biotech companies
Insight into the terms included in a M&A agreement, together with real world clause examples
Full listing of M&A deals by company A-Z and industry sector
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Pharma and Biotech MandA Trends 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in MandA dealmaking
2.1. Introduction
2.2. Difference between merger and acquisition deals
2.3. Trends in MandA deals since 2010
2.3.1. Japanese MandA accelerates
2.3.2. Option to acquire the new acquisition?
2.3.3. Case study 1: Cephalon - Ception
2.3.4. Case study 2: HertArt Aps - Vitrolife
2.4. When MandA can be useful
2.5. Attributes of MandA deals
2.5.1. MandA as an alternative to IPO
2.6. Partnering deals with MandA component
2.6.1. Partnering as a precursor to MandA
2.6.1.a. Case study 3: Celgene - VentiRx Pharmaceuticals, Oct 2012
2.6.2. Equity as part of partnering deal
2.6.2.a. Case study 4: BioMarin - Catalyst Pharma Partners, Oct 2012
2.6.2.b. Case study 5: Pfizer - Clovis Oncology , June 2011
2.6.2.c. Case study 6: Tesaro - OPKO Health, December 2010
2.6.3. Conversion of partnership to acquisition
2.6.4. But MandA is not always the route followed
2.7. Big pharma mega mergers - are we at the end of the road?
2.7.1. Growth of Johnson and Johnson through MandA
2.7.2. Growth of Novartis through MandA
2.8. Accessing innovation through MandA
2.8.1. Big pharma acquisitions of small companies
2.8.1.a. Case study 7: Abbott - Facet Biotechnology
2.8.1.b. Case study 8: Gilead Sceinces - Pharmasset
2.8.2. Medium and small biopharma - use of MandA
2.8.2.a. Case study 9: Allergan - MAP Pharmaceuticals
2.8.2.b. Case study 10: Reckitt Benckiser - Schiff Nutrition International
2.8.3. Using MandA to build a company
2.8.3.a. Case study 11: Shire - built from MandA
2.8.3.b. Case study 12: Zeneus - acquiring a ready-made European capability
2.8.3.c. Case study 13: Novartis - from pure pharma to half generic
2.8.4. Emergence of biotech-biotech mergers
2.8.4.a. Case study 14: Merger between Biogen and Idec
2.8.4.b. Case study 15: Amgen acquisition activity
2.9. The emerging role of private equity in MandA
2.10. Implementing MandA transactions
2.11. Joint ventures as alternative to MandA
2.12. The future of MandA in biopharma

Chapter 3 - Overview of MandA deal structure
3.1. Introduction
3.2. Pure versus multi-component acquisition deals
3.3. Pure MandA agreement structure
3.3.1. Example acquisition agreements
3.3.1.a. Case study 16: Allergan - SkinMedica - November 2012
3.4. Acquisition as part of a wider alliance agreement
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 17: MGI Pharma - AkaRx - October 2007
3.5. Merger agreements
3.5.1. Example merger agreements
3.5.1.a. Case study 18: Synergy Pharmaceuticals - Callisto Pharmaceuticals - July 2012

Chapter 4 - Leading MandA deals
4.1. Introduction
4.2. Top MandA deals by value
4.3. Top merger deals
4.4. Most active MandA dealmakers
4.5. Big pharma MandA deal activity
4.6. Big biotech MandA deal activity

Chapter 5 - Big pharma MandA deals
5.1. Introduction
5.2. How to use MandA deals
5.3. Big pharma company MandA deal profiles

Chapter 6 - Big biotech MandA deals
6.1. Introduction
6.2. How to use MandA deals
6.3. Big biotech company MandA deal profiles

Chapter 7 - MandA contracts directory
7.1. Introduction
7.2. Company A-Z
7.3. By industry sector
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

The following appendices are available in a accompanying volume.

Appendices
Appendix 1 - Company A-Z
Appendix 2 - By industry sector
Appendix 3 - MandA dealmaking references
Appendix 4 - Resources
Appendix 5 - Deal type definitions
Appendix 6 - Example MandA contract document


TABLE OF FIGURES

Figure 1: Definition of merger and acquisition
Figure 2: Trends in MandA deal announcements, 2010-2015
Figure 3: MandA deals signed by various industry sectors, 2010-2015
Figure 4: Key recent MandA trends - 2010 to present
Figure 5: Recent Japanese MandA
Figure 6: Recent ‘option to acquire' deals
Figure 7: Situations where MandA can prove useful
Figure 8: Recent partnering deals involving equity participation in the licensor
Figure 9: Equity investments converting to acquisitions
Figure 10: Johnson and Johnson's growth through MandA
Figure 11: Novartis's growth through MandA since 2000
Figure 12: Shire's MandA history
Figure 13: Amgen's biotech-biotech acquisition trail
Figure 14: Private equity MandA activity, 2010-2015
Figure 15: Issues in implementing MandA agreements
Figure 16: Joint venture agreements, 2010-2015
Figure 17: Recent joint ventures in the biopharma sector
Figure 18: Future trends in MandA in biopharma
Figure 19: Components of the acquisition deal structure
Figure 20: Components of the merger deal structure
Figure 21: Top MandA deals by value since 2010
Figure 22: Top merger deals by value since 2010
Figure 23: Most active MandA dealmakers Jan 2010- April 2015
Figure 24: Big pharma - top 50 - MandA deals 2010 to mid 2015
Figure 25: Big pharma MandA deal frequency - 2010 to mid 2015
Figure 26: Big biotech - top 50 - MandA deals 2010 to mid 2015
Figure 27: Big biotech MandA deal frequency - 2010 to mid 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

  • $ 18000
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global bioreactors market is expected to reach to USD 1,417 million by 2021 from USD 955 million in 2015, at a CAGR of 6.8% between 2015 and 2021.The increase in adoption of single-use technologies, ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.